NovoCure (NVCR) Stock Forecast, Price Target & Predictions
NVCR Stock Forecast
NovoCure stock forecast is as follows: an average price target of $68.92 (represents a 315.43% upside from NVCR’s last price of $16.59) and a rating consensus of 'Hold', based on 6 wall street analysts offering a 1-year stock forecast.
NVCR Price Target
The average price target for NovoCure (NVCR) is $68.92 based on 1-year price targets from 6 Wall Street analysts in the past 3 months, with a price target range of $200.00 to $14.50. This represents a potential 315.43% upside from NVCR's last price of $16.59.
NVCR Analyst Ratings
According to 6 Wall Street analysts, NovoCure's rating consensus is 'Hold'. The analyst rating breakdown for NVCR stock is 0 'Strong Buy' (0.00%), 2 'Buy' (33.33%), 3 'Hold' (50.00%), 1 'Sell' (16.67%), and 0 'Strong Sell' (0.00%).
NovoCure Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Oct 16, 2024 | Emily Bodnar | H.C. Wainwright | $30.00 | $17.78 | 68.73% | 80.83% |
| Jul 26, 2024 | Emily Bodnar | H.C. Wainwright | $24.00 | $18.25 | 31.47% | 44.67% |
| May 03, 2024 | Emily Bodnar | H.C. Wainwright | $22.00 | $14.19 | 55.04% | 32.61% |
| May 02, 2024 | Vijay Kumar | Evercore ISI | $14.50 | $14.78 | -1.89% | -12.60% |
| Apr 10, 2024 | Jason Bednar | Piper Sandler | $28.00 | $14.88 | 88.17% | 68.78% |
| Apr 03, 2024 | Larry Biegelsen | Wells Fargo | $42.00 | $14.39 | 191.87% | 153.16% |
| Mar 27, 2024 | - | H.C. Wainwright | $24.00 | $14.64 | 63.93% | 44.67% |
| Jan 06, 2023 | - | J.P. Morgan | $99.00 | $109.04 | -9.21% | 496.75% |
| Jan 06, 2023 | - | Wells Fargo | $107.00 | $118.81 | -9.94% | 544.97% |
| Jan 05, 2023 | Emily Bodnar | H.C. Wainwright | $140.00 | $107.44 | 30.31% | 743.88% |
The latest NovoCure stock forecast, released on Oct 16, 2024 by Emily Bodnar from H.C. Wainwright, set a price target of $30.00, which represents a 68.73% increase from the stock price at the time of the forecast ($17.78), and a 80.83% increase from NVCR last price ($16.59).
NovoCure Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 1 | 7 |
| Avg Price Target | $30.00 | $30.00 | $26.36 |
| Last Closing Price | $16.59 | $16.59 | $16.59 |
| Upside/Downside | 80.83% | 80.83% | 58.89% |
In the current month, the average price target of NovoCure stock is $30.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 80.83% increase as opposed to NovoCure's last price of $16.59. This month's average price target is down 0.00% compared to last quarter, and up 13.81% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 31, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Oct 16, 2024 | H.C. Wainwright | Neutral | Buy | Upgrade |
| Jul 26, 2024 | H.C. Wainwright | Neutral | Neutral | Hold |
| Jul 02, 2024 | Piper Sandler | Neutral | Neutral | Hold |
| Jul 02, 2024 | H.C. Wainwright | Underperform | Underperform | Hold |
| Jun 04, 2024 | Wells Fargo | Neutral | Neutral | Hold |
| May 24, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| May 03, 2024 | H.C. Wainwright | Neutral | Neutral | Hold |
| May 02, 2024 | Wells Fargo | Buy | Buy | Hold |
| May 02, 2024 | Evercore ISI | Negative | Negative | Hold |
NovoCure's last stock rating was published by H.C. Wainwright on Oct 31, 2024. The company gave NVCR a "Buy" rating, the same as its previous rate.
NovoCure Financial Forecast
NovoCure Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $127.32M | $126.05M | $122.18M | $128.43M | $131.00M | $140.87M | $137.55M | $133.21M | $133.61M | $133.52M | $134.69M | $143.95M | $132.66M | $115.92M | $101.83M | $99.23M | $92.06M | $86.71M | $73.31M | $52.13M | $34.88M |
| Avg Forecast | $162.05M | $159.55M | $156.85M | $155.00M | $153.04M | $143.95M | $135.83M | $131.44M | $133.80M | $128.75M | $124.25M | $127.77M | $128.40M | $130.61M | $134.97M | $134.08M | $133.00M | $141.27M | $141.50M | $138.70M | $144.00M | $119.51M | $105.70M | $101.92M | $99.20M | $86.94M | $78.98M | $72.74M | $44.66M | $39.86M |
| High Forecast | $165.28M | $162.73M | $159.98M | $157.50M | $157.23M | $143.99M | $135.83M | $131.44M | $133.85M | $137.79M | $126.73M | $130.32M | $130.96M | $130.61M | $134.97M | $134.08M | $133.00M | $141.27M | $141.50M | $138.70M | $144.00M | $119.51M | $105.70M | $101.92M | $99.20M | $86.94M | $78.98M | $72.74M | $53.59M | $47.84M |
| Low Forecast | $158.18M | $155.74M | $153.11M | $152.49M | $145.23M | $143.90M | $135.83M | $131.44M | $133.75M | $123.39M | $121.29M | $124.72M | $125.34M | $130.61M | $134.97M | $134.08M | $133.00M | $141.27M | $141.50M | $138.70M | $144.00M | $119.51M | $105.70M | $101.92M | $99.20M | $86.94M | $78.98M | $72.74M | $35.73M | $31.89M |
| # Analysts | 1 | 1 | 1 | 2 | 6 | 3 | 1 | 1 | 2 | 6 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 16 | 8 | 11 | 7 | 11 | 7 | 7 | 17 | 15 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.99% | 1.01% | 0.96% | 1.00% | 1.00% | 1.04% | 1.03% | 1.00% | 0.95% | 0.94% | 0.97% | 1.00% | 1.11% | 1.10% | 1.00% | 1.00% | 1.06% | 1.10% | 1.01% | 1.17% | 0.88% |
NovoCure's average Quarter revenue forecast for Dec 23 based on 2 analysts is $133.80M, with a low forecast of $133.75M, and a high forecast of $133.85M. NVCR's average Quarter revenue forecast represents a 5.09% increase compared to the company's last Quarter revenue of $127.32M (Sep 23).
NovoCure EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 6 | 3 | 1 | 1 | 2 | 6 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 16 | 8 | 11 | 7 | 11 | 7 | 7 | 17 | 15 |
| EBITDA | - | - | - | - | - | - | - | - | - | $-55.44M | $-62.66M | $-60.25M | $-42.98M | $-21.95M | $-18.47M | $1.80M | $-22.91M | $-7.80M | $-10.76M | $-364.00K | $11.30M | $13.23M | $6.65M | $-3.92M | $875.00K | $3.23M | $2.09M | $-6.56M | $-15.33M | $-14.16M |
| Avg Forecast | $-17.41M | $-17.14M | $-16.85M | $-16.65M | $-16.44M | $-15.47M | $-14.59M | $-2.66M | $-14.38M | $-13.83M | $-13.35M | $-2.41M | $-13.86M | $-14.03M | $-14.50M | $-2.58M | $-14.29M | $-15.18M | $-15.20M | $-1.31M | $-15.47M | $-12.84M | $-11.36M | $-4.32M | $-10.66M | $-9.34M | $-8.49M | $-7.03M | $-12.76M | $-15.93M |
| High Forecast | $-17.00M | $-16.73M | $-16.45M | $-16.39M | $-15.61M | $-15.46M | $-14.59M | $-2.12M | $-14.37M | $-13.26M | $-13.03M | $-1.93M | $-11.09M | $-14.03M | $-14.50M | $-2.07M | $-14.29M | $-15.18M | $-15.20M | $-1.05M | $-15.47M | $-12.84M | $-11.36M | $-3.45M | $-10.66M | $-9.34M | $-8.49M | $-5.62M | $-10.21M | $-12.74M |
| Low Forecast | $-17.76M | $-17.49M | $-17.19M | $-16.92M | $-16.89M | $-15.47M | $-14.59M | $-3.19M | $-14.38M | $-14.81M | $-13.62M | $-2.90M | $-16.63M | $-14.03M | $-14.50M | $-3.10M | $-14.29M | $-15.18M | $-15.20M | $-1.57M | $-15.47M | $-12.84M | $-11.36M | $-5.18M | $-10.66M | $-9.34M | $-8.49M | $-8.43M | $-15.32M | $-19.11M |
| Surprise % | - | - | - | - | - | - | - | - | - | 4.01% | 4.69% | 24.95% | 3.10% | 1.56% | 1.27% | -0.70% | 1.60% | 0.51% | 0.71% | 0.28% | -0.73% | -1.03% | -0.59% | 0.91% | -0.08% | -0.35% | -0.25% | 0.93% | 1.20% | 0.89% |
4 analysts predict NVCR's average Quarter EBITDA for Jun 22 to be $-14.50M, with a high of $-14.50M and a low of $-14.50M. This is -903.89% lower than NovoCure's previous annual EBITDA (Mar 22) of $1.80M.
NovoCure Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 6 | 3 | 1 | 1 | 2 | 6 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 16 | 8 | 11 | 7 | 11 | 7 | 7 | 17 | 15 |
| Net Income | - | - | - | - | - | - | - | - | - | $-49.48M | $-57.42M | $-53.06M | $-37.30M | $-26.58M | $-24.01M | $-4.65M | $-26.46M | $-13.12M | $-14.64M | $-4.13M | $4.92M | $9.28M | $1.66M | $3.95M | $4.26M | $1.93M | $-1.27M | $-12.15M | $-20.72M | $-18.05M |
| Avg Forecast | $-44.38M | $-40.77M | $-41.13M | $-41.49M | $-38.35M | $-36.13M | $-43.61M | $-7.65M | $-56.44M | $-56.83M | $-54.12M | $-6.95M | $-16.01M | $-28.16M | $-15.62M | $-7.44M | $-11.04M | $-7.95M | $943.56K | $-14.86M | $13.52M | $4.19M | $-403.88K | $4.35M | $1.69M | $-4.77M | $-7.85M | $-13.02M | $-17.26M | $-20.30M |
| High Forecast | $-43.00M | $-39.51M | $-39.86M | $-34.58M | $-29.59M | $-35.01M | $-42.26M | $-6.12M | $-50.05M | $-46.99M | $-52.44M | $-5.56M | $-12.81M | $-28.16M | $-15.62M | $-5.95M | $-11.04M | $-7.95M | $943.56K | $-11.89M | $13.52M | $4.19M | $-403.88K | $5.22M | $1.69M | $-4.77M | $-7.85M | $-10.41M | $-13.81M | $-16.24M |
| Low Forecast | $-45.53M | $-41.83M | $-42.20M | $-47.26M | $-44.93M | $-37.07M | $-44.74M | $-9.18M | $-64.96M | $-62.29M | $-55.53M | $-8.34M | $-19.21M | $-28.16M | $-15.62M | $-8.92M | $-11.04M | $-7.95M | $943.56K | $-17.83M | $13.52M | $4.19M | $-403.88K | $3.48M | $1.69M | $-4.77M | $-7.85M | $-15.62M | $-20.71M | $-24.36M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.87% | 1.06% | 7.63% | 2.33% | 0.94% | 1.54% | 0.63% | 2.40% | 1.65% | -15.52% | 0.28% | 0.36% | 2.22% | -4.10% | 0.91% | 2.52% | -0.40% | 0.16% | 0.93% | 1.20% | 0.89% |
NovoCure's average Quarter net income forecast for Mar 21 is $-14.86M, with a range of $-17.83M to $-11.89M. NVCR's average Quarter net income forecast represents a -402.23% decrease compared to the company's last Quarter net income of $4.92M (Dec 20).
NovoCure SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 6 | 3 | 1 | 1 | 2 | 6 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 16 | 8 | 11 | 7 | 11 | 7 | 7 | 17 | 15 |
| SG&A | - | - | - | - | - | - | - | - | - | $99.85M | $99.27M | $93.11M | $87.70M | $73.90M | $76.42M | $68.39M | $69.99M | $63.81M | $66.90M | $62.48M | $59.72M | $56.42M | $53.87M | $55.44M | $50.55M | $46.54M | $44.96M | $42.57M | $35.46M | $27.18M |
| Avg Forecast | $91.09M | $89.69M | $88.17M | $87.13M | $86.03M | $80.91M | $76.35M | $112.55M | $75.21M | $72.37M | $69.84M | $102.31M | $42.35M | $73.42M | $75.87M | $109.43M | $74.76M | $79.41M | $79.54M | $77.97M | $80.94M | $67.18M | $59.41M | $60.99M | $55.76M | $48.87M | $44.40M | $45.61M | $29.53M | $30.58M |
| High Forecast | $92.91M | $91.48M | $89.93M | $88.53M | $88.38M | $80.94M | $76.35M | $135.06M | $75.24M | $77.45M | $71.24M | $122.78M | $50.81M | $73.42M | $75.87M | $131.31M | $74.76M | $79.41M | $79.54M | $77.97M | $80.94M | $67.18M | $59.41M | $73.18M | $55.76M | $48.87M | $44.40M | $54.73M | $35.44M | $36.69M |
| Low Forecast | $88.92M | $87.55M | $86.06M | $85.72M | $81.64M | $80.89M | $76.35M | $90.04M | $75.18M | $69.36M | $68.18M | $81.85M | $33.88M | $73.42M | $75.87M | $87.54M | $74.76M | $79.41M | $79.54M | $77.97M | $80.94M | $67.18M | $59.41M | $48.79M | $55.76M | $48.87M | $44.40M | $36.49M | $23.62M | $24.46M |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.38% | 1.42% | 0.91% | 2.07% | 1.01% | 1.01% | 0.63% | 0.94% | 0.80% | 0.84% | 0.80% | 0.74% | 0.84% | 0.91% | 0.91% | 0.91% | 0.95% | 1.01% | 0.93% | 1.20% | 0.89% |
NovoCure's average Quarter SG&A projection for Dec 23 is $75.21M, based on 2 Wall Street analysts, with a range of $75.18M to $75.24M. The forecast indicates a -24.68% fall compared to NVCR last annual SG&A of $99.85M (Sep 23).
NovoCure EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 6 | 3 | 1 | 1 | 2 | 6 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 16 | 8 | 11 | 7 | 11 | 7 | 7 | 17 | 15 |
| EPS | - | - | - | - | - | - | - | - | - | $-0.46 | $-0.54 | $-0.50 | $-0.36 | $-0.25 | $-0.23 | $-0.04 | $-0.25 | $-0.13 | $-0.14 | $-0.04 | $0.05 | $0.09 | $0.02 | $0.04 | $0.04 | $0.02 | $-0.01 | $-0.13 | $-0.23 | $-0.21 |
| Avg Forecast | $-0.41 | $-0.38 | $-0.38 | $-0.38 | $-0.35 | $-0.33 | $-0.40 | $-0.42 | $-0.52 | $-0.53 | $-0.50 | $-0.32 | $-0.30 | $-0.26 | $-0.14 | $-0.18 | $-0.10 | $-0.07 | $0.01 | $0.01 | $0.13 | $0.04 | $-0.00 | $0.03 | $0.02 | $-0.04 | $-0.07 | $-0.14 | $-0.11 | $-0.27 |
| High Forecast | $-0.40 | $-0.36 | $-0.37 | $-0.32 | $-0.27 | $-0.32 | $-0.39 | $-0.41 | $-0.46 | $-0.43 | $-0.48 | $-0.31 | $-0.29 | $-0.26 | $-0.14 | $-0.18 | $-0.10 | $-0.07 | $0.01 | $0.01 | $0.13 | $0.04 | $-0.00 | $0.03 | $0.02 | $-0.04 | $-0.07 | $-0.14 | $-0.09 | $-0.22 |
| Low Forecast | $-0.42 | $-0.39 | $-0.39 | $-0.44 | $-0.42 | $-0.34 | $-0.41 | $-0.43 | $-0.60 | $-0.58 | $-0.51 | $-0.33 | $-0.31 | $-0.26 | $-0.14 | $-0.18 | $-0.10 | $-0.07 | $0.01 | $0.01 | $0.13 | $0.04 | $-0.00 | $0.03 | $0.02 | $-0.04 | $-0.07 | $-0.14 | $-0.13 | $-0.32 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.88% | 1.08% | 1.55% | 1.19% | 0.96% | 1.59% | 0.24% | 2.44% | 1.76% | -15.98% | -2.67% | 0.40% | 2.31% | -5.33% | 1.17% | 2.55% | -0.45% | 0.14% | 0.91% | 2.09% | 0.78% |
According to 3 Wall Street analysts, NovoCure's projected average Quarter EPS for Mar 21 is $0.01, with a low estimate of $0.01 and a high estimate of $0.01. This represents a -70.00% decrease compared to NVCR previous annual EPS of $0.05 (Dec 20).
NovoCure Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| NVCR | NovoCure | $16.59 | $68.92 | 315.43% | Hold |
| INMD | InMode | $17.38 | $27.50 | 58.23% | Hold |
| TMDX | TransMedics Group | $84.97 | $126.75 | 49.17% | Buy |
| IRTC | iRhythm | $81.44 | $121.17 | 48.78% | Buy |
| LIVN | LivaNova | $49.01 | $70.50 | 43.85% | Buy |
| CNMD | CONMED | $70.47 | $96.00 | 36.23% | Buy |
| NARI | Inari Medical | $48.93 | $66.11 | 35.11% | Buy |
| INSP | Inspire Medical Systems | $192.71 | $238.00 | 23.50% | Buy |
| PODD | Insulet | $237.44 | $270.93 | 14.10% | Buy |
| ITGR | Integer | $126.53 | $138.00 | 9.07% | Buy |
| MASI | Masimo | $147.39 | $160.20 | 8.69% | Buy |
| GMED | Globus Medical | $74.72 | $79.54 | 6.45% | Buy |
| PEN | Penumbra | $229.51 | $224.85 | -2.03% | Buy |
| SWAV | ShockWave Medical | $334.75 | $258.17 | -22.88% | Hold |
NVCR Forecast FAQ
Is NovoCure a good buy?
No, according to 6 Wall Street analysts, NovoCure (NVCR) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 33.33% of NVCR's total ratings.
What is NVCR's price target?
NovoCure (NVCR) average price target is $68.92 with a range of $14.5 to $200, implying a 315.43% from its last price of $16.59. The data is based on 6 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will NovoCure stock go up soon?
According to Wall Street analysts' prediction for NVCR stock, the company can go up by 315.43% (from the last price of $16.59 to the average price target of $68.92), up by 1105.55% based on the highest stock price target, and down by -12.60% based on the lowest stock price target.
Can NovoCure stock reach $20?
NVCR's average twelve months analyst stock price target of $68.92 supports the claim that NovoCure can reach $20 in the near future.
What is NovoCure's current price target trend?
1 Wall Street analyst forecast a $30 price target for NovoCure (NVCR) this month, up 80.83% from its last price of $16.59. Compared to the last 3 and 12 months, the average price target increased by 80.83% and increased by 58.89%, respectively.
What are NovoCure's analysts' financial forecasts?
NovoCure's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $564.26M (high $568.49M, low $556.41M), average EBITDA is $-49.162M (high $-47.787M, low $-50.148M), average net income is $-126M (high $-113M, low $-136M), average SG&A $355.84M (high $380.73M, low $328.91M), and average EPS is $-1.511 (high $-1.394, low $-1.602). NVCR's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $633.45M (high $645.5M, low $619.52M), average EBITDA is $-68.064M (high $-66.568M, low $-69.359M), average net income is $-168M (high $-157M, low $-177M), average SG&A $356.07M (high $362.84M, low $348.24M), and average EPS is $-1.55 (high $-1.45, low $-1.634).
Did the NVCR's actual financial results beat the analysts' financial forecasts?
Based on NovoCure's last annual report (Dec 2022), the company's revenue was $537.84M, beating the average analysts forecast of $528.05M by 1.85%. Apple's EBITDA was $-89.523M, beating the average prediction of $-44.977M by 99.04%. The company's net income was $-92.534M, beating the average estimation of $-67.215M by 37.67%. Apple's SG&A was $306.41M, beating the average forecast of $301.06M by 1.78%. Lastly, the company's EPS was $-0.88, missing the average prediction of $-0.894 by -1.56%. In terms of the last quarterly report (Sep 2023), NovoCure's revenue was $127.32M, missing the average analysts' forecast of $128.75M by -1.11%. The company's EBITDA was $-55.442M, beating the average prediction of $-13.834M by 300.76%. NovoCure's net income was $-49.485M, missing the average estimation of $-56.83M by -12.92%. The company's SG&A was $99.85M, beating the average forecast of $72.37M by 37.97%. Lastly, the company's EPS was $-0.46, missing the average prediction of $-0.525 by -12.38%